ArkBio在中国对AK0610进行第二阶段试验,AK0610是一种长效单克隆抗体,可以防止婴儿的RSV。 ArkBio launches Phase II trial in China for AK0610, a long-acting monoclonal antibody to prevent RSV in infants.

ArkBio已开始在中国进行第二阶段临床试验,测试AK0610,这是一种用于婴儿呼吸道同步病毒(RSV)的预防性单克隆抗体。 ArkBio has started a Phase II clinical trial in China testing AK0610, a preventive monoclonal antibody for respiratory syncytial virus (RSV) in infants. 该试验涉及五个地点,正在评估该药物对健康婴儿的安全性、耐受性和药效动力学。 The trial, involving five sites, is evaluating the drug’s safety, tolerability, and pharmacokinetics in healthy babies. AK0610是针对RSV输入前F蛋白质的AK0610,是婴儿免疫反应的产物,是针对RSV B菌株的较长期保护和活动设计的。 AK0610 targets the RSV pre-fusion F protein and was derived from an infant’s immune response, engineered for longer protection and activity against RSV B strains. 以往的成人数据显示,抗病毒效果强劲,安全情况有利,表明单剂量可以在整个RSV季节保护婴儿。 Previous data in adults showed strong antiviral effects and a favorable safety profile, suggesting a single dose could protect infants through the RSV season. 这项研究由中国儿科医院牵头,旨在为婴儿开发一种长效、国内生产的预防性治疗。 The study is led by Chinese pediatric hospitals and aims to develop a long-acting, domestically produced preventive therapy for infants.